Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate.
Plaques of psoriasis contain increased levels of cytokines, including tumour necrosis factor-alpha (TNF-alpha), which are thought to be essential to the maintenance of the psoriatic process. We report the successful treatment of severe, recalcitrant psoriasis when infliximab (a monoclonal antibody to TNF-alpha) was used in combination with methotrexate.
Kirby
B
B
Dermatology Centre, University of Manchester, Hope Hospital, Salford, Manchester, UK. bkirby@fs1.ho.man.ac.uk
Marsland
A M
AM
Carmichael
A J
AJ
Griffiths
C E
CE
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D002908:Chronic Disease; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D006801:Humans; D000069285:Infliximab; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D012008:Recurrence; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D008727:Methotrexate